Preclinical results on lead candidate EDIT-401 to be unveiled by Editas Medicine at AHA event

Preclinical results on lead candidate EDIT-401 to be unveiled by Editas Medicine at AHA event
Editas Medicine to share EDIT-401 data

Editas Medicine announced that it will present new preclinical data on EDIT-401, its lead in vivo development candidate, at this year’s American Heart Association Scientific Sessions in Chicago.

The update signals ongoing progress in gene editing research as the company shares its latest findings from its in vivo program. Details about the preclinical data are expected to offer insights into the potential of EDIT-401 for future clinical development.

Editas Medicine previously received clearance to begin its first clinical trial of EDIT-401 targeting hyperlipidemia patients, according to a company announcement. The company has also presented research at the ESGCT 33rd Annual Congress and participated in an investor conference, as detailed in an earlier update. These activities reflect ongoing efforts to advance and communicate its gene editing programs.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.